Adia Med Unveils a Fresh Facelift: New Website by ZenChange Marketing Spotlights Cutting-Edge Regenerative Medicine Studies
MWN-AI** Summary
Adia Nutrition's subsidiary, Adia Med, has announced a comprehensive redesign of its website as part of a new digital strategy in collaboration with ZenChange Marketing. This revamped online platform is now dedicated to enhancing transparency, accessibility, and the dissemination of information regarding Adia Med's clinical studies, particularly in regenerative medicine. Key features of the site include user-friendly navigation, detailed summaries of clinical studies, enrollment information, and educational resources about stem cell therapies.
Among the highlighted initiatives on the website is the Autism Stem Cell Clinical Study (NCT07304440), which is currently recruiting participants. This 24-month study aims to evaluate the effects of AdiaVita, composed of umbilical cord blood-derived stem cells and exosomes, alongside glutathione therapy in children aged 3-12 diagnosed with Autism Spectrum Disorder (ASD). Adia Med has made participation more affordable by reducing the cost to $12,000, which covers three intravenous infusions and study-related procedures, thus enabling quicker research timelines without relying on grants or government funding.
The organization emphasizes that the study is investigational and does not claim to cure or treat ASD, with participants closely monitored by a medical team throughout the process. Adia Med encourages families to consult with their current healthcare providers when considering participation.
In addition to the website launch, ZenChange Marketing will manage Adia Med’s social media channels to ensure consistent and informative communications. This step aims to enhance engagement with potential participants, families, and the healthcare community. For further details, visit Adia Med's website or the corporate site of Adia Nutrition.
MWN-AI** Analysis
Adia Nutrition's (OTCQB: ADIA) recent digital overhaul, marked by a partnership with ZenChange Marketing, signifies a strategic pivot towards greater transparency and accessibility, particularly in its clinical research areas. This move is crucial as it aligns with industry trends emphasizing consumer trust and information availability in the healthcare sector.
The relaunch of Adia Med’s website showcases detailed information about investigational studies, including the Autism Stem Cell Clinical Study, which may entice both potential participants and investors. The focus on a patient-pay model for this study, while maintaining affordability, reflects an innovative approach to maintaining control over the research timeline and outcomes. This strategy could also bolster future insurance coverage for regenerative therapies, opening new revenue avenues.
For investors, ADIA's commitment to transparency and participant safety could enhance the company's reputation, potentially leading to increased investor interest. The rigorous management of the clinical studies and the clear communication of their investigational nature further supports this aspect. Such measures could mitigate risks typically associated with biotech investments, providing a safer profile for potential shareholders.
Moreover, the decision to update social media channels to deliver consistent content aligns with contemporary marketing strategies that favor engaging and educational communication. This could improve patient recruitment efforts and strengthen the community's understanding of regenerative treatments, enhancing market presence.
Given the anticipated interventional phase set to begin in May 2026, there may be significant opportunities for ADIA to capitalize on emerging trends in regenerative medicine. Investors should closely monitor developments related to the clinical study outcomes and expansion of Adia Med's services, as positive results could catalyze share price appreciation. Overall, while careful consideration of inherent risks in the biotech space is necessary, the recent developments from Adia Med warrant a cautious optimism for stakeholders.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
Orlando, Florida--(Newsfile Corp. - March 9, 2026) - Adia Nutrition's (OTCQB: ADIA) subsidiary, Adia Med, has launched a complete digital refresh of its online presence. Through a strategic partnership with ZenChange Marketing, Adia Med has relaunched its website with a modern, streamlined design focused on transparency, accessibility, and clear information about its investigational studies. The update makes it easier for families, researchers, and healthcare professionals to explore the organization's dedication to scientific integrity and participant safety.
To view an enhanced version of this graphic, please visit:
https://images.newsfilecorp.com/files/10520/287751_adia.jpg
The redesigned website, now managed and optimized by ZenChange Marketing, serves as the primary hub for Adia Med's current and upcoming clinical research efforts. Visitors will find intuitive navigation, detailed study summaries, eligibility criteria, enrollment information, educational content on stem cell therapies, and timely updates. ZenChange Marketing has also taken over management of all Adia Nutrition and Adia Med social media channels to deliver consistent, engaging, and informative content across platforms.
A central feature of the refreshed site is the dedicated section for Adia Med's Autism Stem Cell Clinical Study (NCT07304440), where recruitment is currently active. This investigational 24-month study examines the potential of AdiaVita, umbilical cord blood-derived stem cells and exosomes, combined with glutathione therapy in children ages 3-12 with Autism Spectrum Disorder (ASD). The protocol includes three monthly AdiaVita stem cell IV infusions, with a one-time participation cost of $12,000 covering all three IVs and study-related procedures.
Adia Med has significantly reduced the price of the study to make it as affordable as possible while still covering essential overhead costs. The organization has selected this patient-pay model without grants or government funding to retain full control over the research timeline, enabling faster completion, quicker publication of results, and stronger momentum toward potential future insurance coverage for these regenerative therapies. The interventional phase is anticipated to begin in May 2026, conducted under strict medical oversight and established clinical protocols.
Adia Med stresses that this remains an investigational study only-it makes no claims to cure, treat, or guarantee outcomes for ASD. Participants receive close monitoring by a dedicated medical team, and the investigational nature of regenerative medicine is fully explained prior to enrollment to support informed decision-making.
Participation is entirely voluntary, and families may withdraw at any time. Adia Med strongly recommends that participants continue care with their existing physicians and specialists and consult them regarding involvement in clinical research.
For full details on the updated website, the Autism Stem Cell Clinical Study, or other Adia Med initiatives, visit www.adiamed.com or the main corporate site at www.adianutrition.com. Inquiries about participation can be directed to:
Phone: (321) 231-2843
Email: research@adiamed.com
About Adia Med
Adia Med advances regenerative medicine through innovative therapies and structured clinical research. The organization prioritizes transparency, medical oversight, scientific integrity, and participant safety, with investigational studies designed to expand understanding of regenerative approaches while upholding clear communication and informed consent.
About ZenChange Marketing
ZenChange Marketing is a marketing and digital strategy firm that helps healthcare organizations, professional firms, and small businesses build trust and grow through clear messaging and user-focused design. ZenChange partners with clients to create online experiences that inform, educate, and support their audiences.
For questions, inquiries, or additional information, please contact Larry Powalisz at ceo@adiamed.com or by phone at 321-788-0850.
Clinic owners and healthcare practitioners interested in licensing the Adia Med name or integrating Adia's regenerative therapies into their practice are encouraged to reach out directly. Strategic partnerships are welcomed as part of Adia's continued mission to expand access to advanced stem cell solutions.
About ADIA Nutrition Inc.:
Adia Nutrition Inc. (OTCQB: ADIA), based in Winter Park, Florida, is a publicly traded company advancing healthcare through innovation. The company specializes in sales of stem cell and regenerative products, such as AdiaVita and AdiaLink, through its lab division, Adia Labs LLC, which is expanding to include insurance-billable wound care products. Adia is also growing nationwide with Adia Med clinics, specializing in orthopedic, pain management, and wound repair. Adia Med clinics also offer specialized regenerative treatments like stem cell therapies and platelet-rich plasma (PRP), advanced treatments including therapeutic plasma exchange (TPE) and autologous hematopoietic stem cell transplantation (aHSCT), and wound repair services.
Revenue is generated through service fees, product sales, equity stakes, and billing insurance for healthcare treatments. Additionally, Adia Nutrition Inc. invests in aligned businesses such as Cement Factory LLC, a nutrition and supplement company with shared values and a focus on health and wellness. Through bold partnerships with top-tier medical entities and unwavering dedication to standardized, FDA-approved lab protocols, Adia Nutrition Inc. is revolutionizing healthcare, igniting a nationwide movement to empower communities with groundbreaking regenerative solutions and vibrant, holistic wellness.
Website: www.adianutrition.com
Website: www.adiamed.com
Website: www.adialabs.com
Website: www.cementfactory.co
Twitter (X): @ADIA_Nutrition
Safe Harbor: This Press Release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are based on the current plans and expectations of management and are subject to a few uncertainties and risks that could significantly affect the company's current plans and expectations, as well as future results of operations and financial condition. A more extensive listing of risks and factors that may affect the company's business prospects and cause actual results to differ materially from those described in the forward-looking statements can be found in the reports and other documents filed by the company with the Securities and Exchange Commission and OTC Markets, Inc. OTC Disclosure and News Service. The company undertakes no obligation to publicly update or revise any forward-looking statements, because of new information, future events or otherwise.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/287751
FAQ**
How does Adia Nutrition Inc (OTCQB: ADIA) plan to leverage its recent digital refresh to attract families and researchers in Orlando, Florida, to its clinical studies and treatments?
What impact is the pricing reduction for the Autism Stem Cell Clinical Study by Adia Nutrition Inc ADIA expected to have on participation rates in the Orlando area?
How will the strategic partnership with ZenChange Marketing enhance Adia Nutrition Inc ADIA's outreach and engagement within the healthcare community in Orlando, Florida?
What specific safety protocols and medical oversight measures are in place for participants in the Autism Stem Cell Clinical Study conducted by Adia Nutrition Inc ADIA in Orlando?
**MWN-AI FAQ is based on asking OpenAI questions about Adia Nutrition Inc (OTC: ADIA).
NASDAQ: ADIA
ADIA Trading
-14.57% G/L:
$0.1835 Last:
59,242 Volume:
$0.21125 Open:
